Skip to main content

Market Overview

Recap: ADMA Biologics Q1 Earnings


Shares of ADMA Biologics (NASDAQ:ADMA) increased in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 38.46% over the past year to ($0.16), which beat the estimate of ($0.17).

Revenue of $16,049,000 rose by 57.34% from the same period last year, which beat the estimate of $14,580,000.

Looking Ahead

ADMA Biologics hasn't issued any earnings guidance for the time being.

ADMA Biologics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: May 12, 2021

Time: 04:30 PM

ET Webcast URL:

Price Action

Company's 52-week high was at $4.20

Company's 52-week low was at $1.45

Price action over last quarter: down 5.52%

Company Description

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipate providing contract filling, labeling and packing services.


Related Articles (ADMA)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings